Milestone Q3: CFO and CMO Out, 30% Cost Cut, RTW PIK Extended to 2029
MIST is trading near its 52-week low of $0.631 (11% above the low).
Summary
Milestone's Q3 8-K discloses the departure of its CFO and CMO, a ~30% operating expense cut, and an RTW amendment extending PIK interest to March 2029 — extending cash runway into late 2028, past the 2H 2028 AFib-RVR Phase 3 readout.
Key Events · Earnings and Guidance · MIST
-
CFO and CMO Depart
CFO Amit Hasija and CMO David Bharucha have left the leadership team; Anthony Krick, VP of Finance, becomes Principal Financial and Principal Accounting Officer.
-
RTW PIK Period Extended to 2029
An amendment to the Note Purchase Agreement with RTW Investments extends the payment-in-kind interest period on the $60.2 million senior secured convertible notes from March 31, 2027 to March 2029.
-
30% Cost Cut, $2M One-Time Charges
Operating expenses are to fall by approximately 30%, with about $2 million of one-time severance and conversion charges, completed by Q1 2027; the ~45-rep sales force moves in-house.
-
Cash Runway Into Late 2028
$145.4 million of cash, equivalents and short-term investments at September 30, 2026 is expected to fund operations into late 2028, more than one year beyond prior guidance and past the 2H 2028 ReVeRA-301 readout.
Analysis · MIST · Life Sciences
The quarter itself was already public this morning via the 10-Q and press release, but this 8-K carries the pieces that change the story: both the CFO and CMO are gone, and RTW agreed to push payment-in-kind interest on the $60.2 million convertible notes from March 2027 to March 2029. That debt relief, combined with a roughly 30% operating expense cut, is what lets management claim cash lasts into late 2028 — past the ReVeRA-301 readout expected in the second half of 2028. The trade-off is a thinner leadership bench and a company that now depends on one commercial product and one Phase 3 program, with a Nasdaq sub-$1.00 notice already outstanding from October 23, 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIST was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.6M. The 52-week trading range was $0.63 to $3.06. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.